Phase 1 Pembrolizumab, Cisplatin, and IMRT for Head and Neck Cancer

Share this content:
Researchers are evaluating the safety, optimal dose, and efficacy of pembrolizumab combined with cisplatin and IMRT among patients with head and neck cancer.
Researchers are evaluating the safety, optimal dose, and efficacy of pembrolizumab combined with cisplatin and IMRT among patients with head and neck cancer.

Title: A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-risk Head and Neck Squamous Cell Carncinoma (HNSCC)1

Principal Investigators: Julie Bauman, NRG Oncology

Description: For this phase 1, dose-expansion trial, researchers are evaluating the safety, optimal dose, and efficacy of pembrolizumab combined with cisplatin and intensity-modulated radiation therapy (IMRT) among patients with head and neck cancer. Eligible patients much have stage III/IV/IVA/IVB squamous cell carcinoma.

This study has 1 arm: patients will receive intravenous cisplatin once weekly for 6 weeks followed by intravenous pembrolizumab every 3 weeks thereafter through week 21. IMRT will be administered during weeks 1 to 6.

The primary objective is to determine the optimal dosage of pembrolizumab based on dose-limiting toxicity. Secondary objectives include disease-free survival, toxicity, and the relationship between PD-L1 expression and disease-free survival.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02775812.

Status: This study is open and recruiting participants as of May 10, 2017.

This study is sponsored by the National Cancer Institute.

Reference

  1. Clinicaltrials.gov. Cisplatin, intensity-modulated radiation therapy, and pembrolizumab in treating patients with stage III-IV head and neck squamous cell carcinoma. NCT02775812. https://clinicaltrials.gov/ct2/show/NCT02775812. Accessed May 10, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters